JP3032274B2 - 新規なピリドン誘導体、その製造方法及び中間体、それらの薬剤としての使用並びにそれらを含有する組成物 - Google Patents

新規なピリドン誘導体、その製造方法及び中間体、それらの薬剤としての使用並びにそれらを含有する組成物

Info

Publication number
JP3032274B2
JP3032274B2 JP2275504A JP27550490A JP3032274B2 JP 3032274 B2 JP3032274 B2 JP 3032274B2 JP 2275504 A JP2275504 A JP 2275504A JP 27550490 A JP27550490 A JP 27550490A JP 3032274 B2 JP3032274 B2 JP 3032274B2
Authority
JP
Japan
Prior art keywords
compound
formula
group
carbon atoms
isomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2275504A
Other languages
English (en)
Japanese (ja)
Other versions
JPH03133957A (ja
Inventor
フランソワ・クレマンス
ミシェル・フォルタン
オディル・ル・マルトレ
Original Assignee
ヘキスト・マリオン・ルセル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヘキスト・マリオン・ルセル filed Critical ヘキスト・マリオン・ルセル
Publication of JPH03133957A publication Critical patent/JPH03133957A/ja
Application granted granted Critical
Publication of JP3032274B2 publication Critical patent/JP3032274B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2275504A 1989-10-17 1990-10-16 新規なピリドン誘導体、その製造方法及び中間体、それらの薬剤としての使用並びにそれらを含有する組成物 Expired - Fee Related JP3032274B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8913545A FR2653123B1 (fr) 1989-10-17 1989-10-17 Nouveaux derives de la pyridone, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant.
FR89-13545 1989-10-17

Publications (2)

Publication Number Publication Date
JPH03133957A JPH03133957A (ja) 1991-06-07
JP3032274B2 true JP3032274B2 (ja) 2000-04-10

Family

ID=9386472

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2275504A Expired - Fee Related JP3032274B2 (ja) 1989-10-17 1990-10-16 新規なピリドン誘導体、その製造方法及び中間体、それらの薬剤としての使用並びにそれらを含有する組成物

Country Status (16)

Country Link
US (3) US5356907A (de)
EP (1) EP0437120B1 (de)
JP (1) JP3032274B2 (de)
KR (1) KR0169717B1 (de)
AT (1) ATE125796T1 (de)
AU (1) AU642434B2 (de)
CA (1) CA2027702A1 (de)
DE (1) DE69021355T2 (de)
DK (1) DK0437120T3 (de)
ES (1) ES2075180T3 (de)
FR (1) FR2653123B1 (de)
GR (1) GR3017022T3 (de)
HU (1) HU208007B (de)
IE (1) IE69342B1 (de)
RU (1) RU2078082C1 (de)
ZA (1) ZA907736B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2714291B1 (fr) * 1993-12-24 1996-03-01 Roussel Uclaf Application des dérivés de la pyridone à titre de médicaments anesthésiques.
DE19639816A1 (de) 1996-09-27 1998-04-02 Hoechst Ag Antimykotische Mittel mit hoher Wirkstofffreisetzung
US20040039030A1 (en) 1996-09-27 2004-02-26 Hoechst Akeengesellschaft Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis
TW200508224A (en) * 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
JP5014983B2 (ja) 2004-05-07 2012-08-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ １１−ベータヒドロキシステロイドデヒドロゲナーゼ阻害剤としてのピロリジン−２−オン及びピペリジン−２−オン誘導体
UA87328C2 (en) 2004-08-30 2009-07-10 Янссен Фармацевтика Н.В. N-2 adamantanyl-2-phenoxy-acetamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
EP1786774B1 (de) 2004-08-30 2009-10-14 Janssen Pharmaceutica N.V. Derivate von tricyclischem lactam als 11-beta-hydroxysteroid-dehydrogenase-inhibitoren
DE602005017159D1 (de) 2004-08-30 2009-11-26 Janssen Pharmaceutica Nv Oxysteroid-dehydrogenase-inhibitoren
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
US8173666B2 (en) * 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3058986A (en) * 1962-10-16 N-ammoalkyl-x-phenyl-x-lower alkyl-z-
BE571915A (de) * 1957-10-10
US3213098A (en) * 1963-08-30 1965-10-19 Upjohn Co Amino substituted 3h-azepines and their preparation
PH12617A (en) * 1973-04-13 1979-07-05 Thomae Gmbh Dr K Aminobenzyl-amides and salts thereof
GB1532957A (en) * 1974-11-04 1978-11-22 Glaxo Lab Ltd Bis(aminomethyl)naphthalene derivatives
EP0021552B1 (de) * 1977-12-22 1983-01-26 JOHN WYETH & BROTHER LIMITED Hexahydroazepin-, Piperidin- und Pyrrolidin-Derivate und Verfahren zu ihrer Herstellung
DK704488D0 (da) * 1988-12-19 1988-12-19 Novo Industri As Nye n-substituerede azaheterocykliske carboxylsyrer
IE61631B1 (en) * 1988-05-20 1994-11-16 Zambon Spa Compounds with central analgesic activity, process for their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
KR0169717B1 (ko) 1999-01-15
US5395843A (en) 1995-03-07
FR2653123B1 (fr) 1992-01-17
AU642434B2 (en) 1993-10-21
GR3017022T3 (en) 1995-11-30
FR2653123A1 (fr) 1991-04-19
DK0437120T3 (da) 1996-04-09
IE903704A1 (en) 1991-04-24
AU6466990A (en) 1991-04-26
US5559130A (en) 1996-09-24
KR910007912A (ko) 1991-05-30
CA2027702A1 (fr) 1991-04-18
DE69021355D1 (de) 1995-09-07
HU906459D0 (en) 1991-04-29
ATE125796T1 (de) 1995-08-15
ZA907736B (en) 1991-11-27
HUT55379A (en) 1991-05-28
DE69021355T2 (de) 1996-01-25
IE69342B1 (en) 1996-09-04
ES2075180T3 (es) 1995-10-01
RU2078082C1 (ru) 1997-04-27
EP0437120A1 (de) 1991-07-17
EP0437120B1 (de) 1995-08-02
HU208007B (en) 1993-07-28
JPH03133957A (ja) 1991-06-07
US5356907A (en) 1994-10-18

Similar Documents

Publication Publication Date Title
AU2001264977B2 (en) Melanocortin receptor agonists
AU2001249281B2 (en) Spiropiperidine derivatives as melanocortin receptor agonists
JP5094453B2 (ja) メラノコルチン−４受容体作動薬としてのアシル化ピペリジン誘導体
US6350760B1 (en) Substituted piperidines as melanocortin-4 receptor agonists
JP4316238B2 (ja) メラノコルチン−４受容体作動薬としてのアシル化ピペリジン誘導体
EP0389352B1 (de) 4-Fluorbenzolderivate, Herstellungsverfahren und diese enthaltende pharmazeutische Zusammensetzungen
JP2010533666A (ja) メラノコルチン−４受容体モジュレーターとしての置換ヘテロアリールピペリジン誘導体
AU2001264977A1 (en) Melanocortin receptor agonists
JPH03176469A (ja) イソインドロン誘導体
JP2003528088A (ja) メラノコルチン受容体作働薬としての置換ピペリジン類
JP2004538281A (ja) メラノコルチン受容体作動薬としての架橋ピペリジン誘導体
EP1842846A1 (de) Phenylpiperidinderivate als Melanocortin-4 Rezeptor-Modulatoren
JP2004500355A (ja) ニューロンの生長及び伸長を刺激する化合物、組成物及び方法
EP1460069A1 (de) Substituierte Cyclohexyl- und Piperidin-Derivative als Melanocortin-4 Receptor Modulatoren
AU2004222090B2 (en) Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators
JP3032274B2 (ja) 新規なピリドン誘導体、その製造方法及び中間体、それらの薬剤としての使用並びにそれらを含有する組成物
JPH06506956A (ja) ピリドンの新規な誘導体、それらの製造法、得られる新規な中間体、それらの薬剤としての使用及びそれらを含有する製薬組成物
JPH0543576A (ja) ２０，２１−ジノルエブルナメニンの新規の誘導体、それらの製造方法及び得られる新規の中間体、それらの薬剤としての使用並びにそれらを含有する組成物
EP1460070B1 (de) Substituierte Piperidin- und Piperazin-Derivative als Melanocortin-4 Receptor Modulatoren
WO2020115684A1 (en) 6-hydroxy-8-oxatricyclo[3.2.1.02,4]octane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage
JPH05213885A (ja) デカヒドロキノリンの新規な誘導体、それらの製造法、製造中間体、それらの薬剤としての用途及びそれらを含有する組成物
JPH10182644A (ja) 三環性化合物、その製造法及び剤

Legal Events

Date Code Title Description
LAPS Cancellation because of no payment of annual fees